Opinion|Videos|August 29, 2024
Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring
Medical experts discuss navigating chronic GVHD.
Advertisement
Video content above is prompted by the following:
- Dr Holtan: Please address the 3 phases of pathophysiology of cGVHD (early inflammation, chronic inflammation and dysregulated immunity, and aberrant repair and fibrosis) and the interplay between them.
How does inflammation affect different organs? And fibrosis?
- Dr Ali:After confirmed diagnosis, please share your monitoring routine for patients with cGVHD.
- Are there certain symptom scores (eg, Lee skin symptom score) that are associated with better clinical outcomes?
- How do you share responsibility across subspecialty to monitor patients? Or other HCPS?
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
4
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
5